Delving into the Latest Updates on Ibuprofen with Synapse

Overview

Basic Info

SummaryIbuprofen, a small molecule drug, functions as a COX inhibitor. Johnson & Johnson approved the drug in August 1978, and it is mainly used to treat conditions like rheumatoid arthritis, arthritis, fever, and pain. Ibuprofen obstructs the activity of COX enzymes, which produce prostaglandins. These hormones are involved in inflammation and pain signaling. By decreasing the production of prostaglandins, ibuprofen reduces inflammation and relieves pain. Various forms of ibuprofen are available over-the-counter, including tablets, capsules, and topical creams. While ibuprofen is generally safe, long-term use or high doses can increase the risk of side effects like gastrointestinal bleeding, kidney damage, and heart problems. Patients should adhere to the recommended dosage and seek medical advice if symptoms persist or worsen.

Drug Type

Small molecule drug

Synonyms

(4-isobutylphenyl)-α-methylacetic acid, (RS)-ibuprofen, (±)-2-(p-isobutylphenyl)propionic acid

+ [94]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [6]

Active Indication

Ductus Arteriosus, PatentChronic PainJuvenile Idiopathic Arthritis+ [27]

Inactive Indication

Acute PainAcute respiratory infectionsAnalgesia+ [15]

Originator Organization

Johnson & Johnson

Active Organization

Kaken Pharmaceutical Co., Ltd.

Zhongshan Wanhan Pharmaceutical Co., Ltd.

Overseas Pharmaceuticals Ltd.

+ [19]

Inactive Organization

Oxford Pharmascience Ltd.

Apsen Farmaceutica S/ABeijing Alica Pharmaceutical Sci-Tech Co., Ltd.

+ [14]

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1966),

ArthritisFeverPain

RegulationOrphan Drug (US), Priority Review (CN)

Login to view timeline

Structure

Molecular FormulaC13H18O2

InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

CAS Registry15687-27-1

This trial is being completed to compare two commonly used options to treat pain after discharge from surgery. Participants that undergo tonsil removal, gallbladder removal, and knee scope will be eligible to enroll. Eligible participants will be randomized to prescription of 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) plus acetaminophen or low dose opioids with the NSAIDs plus acetaminophen. The key question the study seeks to answer is which option will have the best outcomes and with the fewest side effects?

Start Date01 Jan 2025

Sponsor / Collaborator

University of Michigan

[+1]

NCT06686862 / Not yet recruitingPhase 3IIT

Non-Steroidal Anti-Inflammatory Drugs Versus Conventional Treatment in Acute Myocarditis (INFLAMA Trial)

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of a 3-week ibuprofen tapering regimen compared to conventional analgesic treatment (acetaminophen) in patients with acute myocarditis and left ventricular ejection fraction ≥50%. The objective is to assess the reduction in late gadolinium enhancement on cardiac magnetic resonance imaging at 6-month follow-up.

Start Date01 Dec 2024

Sponsor / Collaborator-

NCT06496854 / Not yet recruitingPhase 2

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

The objective of this pilot study is to discuss the feasibility of prescribing lorazepam prior to IUD insertion and of measuring effect of lorazepam on anxiety and pain with Intrauterine Device (IUD) insertion. The target population for this study will be 25 adult participants scheduled for an IUD insertion at a UW Family Medicine residency clinic. Participants will be followed for 1 appointment visit.

Start Date01 Dec 2024

Sponsor / Collaborator

University of Wisconsin Madison

100 Clinical Results associated with Ibuprofen

Login to view more data

100 Translational Medicine associated with Ibuprofen

Login to view more data

100 Patents (Medical) associated with Ibuprofen

Login to view more data

16,592

Literatures (Medical) associated with Ibuprofen

01 Sep 2025·Neural Regeneration Research

Modulation of the Nogo signaling pathway to overcome amyloid-β-mediated neurite inhibition in human pluripotent stem cell–derived neurites

Article

Author: Goncalves, Kirsty ; Przyborski, Stefan

JOURNAL/nrgr/04.03/01300535-202509000-00026/figure1/v/2024-11-05T132919Z/r/image-tiff Neuronal cell death and the loss of connectivity are two of the primary pathological mechanisms underlying Alzheimer’s disease. The accumulation of amyloid-β peptides, a key hallmark of Alzheimer’s disease, is believed to induce neuritic abnormalities, including reduced growth, extension, and abnormal growth cone morphology, all of which contribute to decreased connectivity. However, the precise cellular and molecular mechanisms governing this response remain unknown. In this study, we used an innovative approach to demonstrate the effect of amyloid-β on neurite dynamics in both two-dimensional and three-dimensional culture systems, in order to provide more physiologically relevant culture geometry. We utilized various methodologies, including the addition of exogenous amyloid-β peptides to the culture medium, growth substrate coating, and the utilization of human-induced pluripotent stem cell technology, to investigate the effect of endogenous amyloid-β secretion on neurite outgrowth, thus paving the way for potential future applications in personalized medicine. Additionally, we also explore the involvement of the Nogo signaling cascade in amyloid-β-induced neurite inhibition. We demonstrate that inhibition of downstream ROCK and RhoA components of the Nogo signaling pathway, achieved through modulation with Y-27632 (a ROCK inhibitor) and Ibuprofen (a Rho A inhibitor), respectively, can restore and even enhance neuronal connectivity in the presence of amyloid-β. In summary, this study not only presents a novel culture approach that offers insights into the biological process of neurite growth and inhibition, but also proposes a specific mechanism for reduced neural connectivity in the presence of amyloid-β peptides, along with potential intervention points to restore neurite growth. Thereby, we aim to establish a culture system that has the potential to serve as an assay for measuring preclinical, predictive outcomes of drugs and their ability to promote neurite outgrowth, both generally and in a patient-specific manner.

01 Jan 2025·Food Chemistry

Green synthesis and two-step chromatographic separation of thiocanthal and thiocanthol: Two novel biologically active sulfur derivatives of oleocanthal and oleacein from extra virgin olive oil

Article

Author: Gasparrini, Francesco ; Dainese, Enrico ; Di Risola, Daniel ; Fontana, Mario ; Federico, Rodolfo ; Mosca, Luciana ; Francioso, Antonio ; Mattioli, Roberto ; Dufrusine, Beatrice ; Pascarella, Gianmarco ; Morea, Veronica ; Ciogli, Alessia ; Villani, Claudio

Oleocanthal and oleacein are the two major secoiridoids exclusively present in extra virgin olive oil (EVOO). Both compounds exert important pharmacological activities, including anti-inflammatory, anti-tumoral, neuro- and cardiovascular protective effects. Due to their enormous potential as possible drugs the extraction of these two bioactive natural products from EVOO has been extensively investigated in the last years and is generally supported by the use of organic chemistry. It is quite difficult to produce large quantities of these two compounds, either by organic solvent extraction and purification or by chemical synthesis, and furthermore organic processes such as cleaning, defatting, and extraction of EVOO pose a threat to the environment and are potentially harmful to workers. In this work we set up a novel aqueous extraction and isolation method from EVOO by transforming oleocanthal and oleacein into two water-soluble sulfonated products. The two derived compounds, here named thiocanthal and thiocanthol, were isolated by a two-step organic free chromatographic strategy, chemically characterized, and evaluated for their inhibitory activity on cyclooxygenase (COX). The results demonstrate that thiocanthal and thiocanthol possess anti-inflammatory effect, which is comparable to their precursors and higher than the well-known non-steroidal anti-inflammatory drug ibuprofen. Computational docking studies were performed to obtain and analyse putative models of the interaction of thiocanthal and thiocanthol with COX-1 and COX-2 binding sites. Predicted binding energy values suggested that both compounds might preferentially bind COX-2, which may have a significant pharmacological impact. Therefore, thiocanthal and thiocanthol, obtained by this novel green process, are extremely interesting both as new bioactive compounds per se and as lead compounds for the development of novel non-steroidal anti-inflammatory drugs (NSAIDs).

01 Jan 2025·Journal of Ethnopharmacology

Bioactive phytocompounds profiling and the evaluation of analgesic, anti-inflammatory, and antihyperglycemic potential of Argyreia capitiformis (Poir.) Ooststr.: A combined n vitro, n vivo, and computational investigations

Article

Author: Islam, Md Naharul ; Biswas, Biswajit ; Islam, Md. Naharul ; Oisay, Debasree Sen ; Hasan, Md. Nazmul ; Hasan, Md Nazmul ; Biswas, Partha ; Medha, Maisha Maliha ; Devnath, Hiron Saraj ; Hossain, Arafat ; Sadhu, Samir Kumar ; Ahmed, Khondoker Shahin ; Hossain, Hemayet

ETHNOPHARMACOLOGICAL RELEVANCEArgyreia capitiformis (Poir.) Ooststr. (Convolvulaceae) is traditionally used by the Chakma community in the hilly region of Bangladesh to treat minor disorders such as pain.AIM OF THE STUDYThis study intended to determine the secondary metabolites to identify bioactive compounds and evaluate antioxidant potential, in vitro anti-inflammatory and in vivo analgesic, anti-inflammatory, and antihyperglycemic activities of A. capitiformis along with in silico investigations.MATERIALS AND METHODSChemical profiling was carried out using HPLC and GC-MS analysis. The analgesic effect was measured employing tail immersion and acetic acid-induced writhing methods. Following protein denaturation and formalin-induced paw edema, anti-inflammatory activity was studied. The antihyperglycemic potential was assessed using an oral glucose tolerance test (OGTT), while further mechanistic investigation was conducted using an alpha-glucosidase enzyme inhibitory assay. Simulations and molecular docking analyses were performed to ascertain the stability and binding affinities of the drug-protein complex.RESULTSA. capitiformis ethanolic extract confirmed the presence of phenolics, alkaloids, flavonoids, terpenoids, tannins, gums, steroids, and reducing sugars. HPLC analysis revealed the presence of eight polyphenolic compounds, the most abundant of which was myricetin (64.10 ± 0.14 mg per 100 g dry extract). Moreover, the GC-MS analysis revealed twenty-four molecules, the most important of which was 2,4-bis (dimethylbenzyl)-6-t-butylphenol (9.19%). The concentrations of total flavonoids, total terpenoids, total phenolics, and total tannins were ascertained to be 142.48 mg QE/g, 173.1 mg UAE/g, 19.35 mg GAE/g, and 13.05 mg GAE/g, respectively. Furthermore, the plant extract had a total antioxidant capacity of 388 mg AAE/g. In the writhing assay, the plant extract suppressed writhing by 59.73% and 76.99% at the doses of 250 and 500 mg/kg, respectively, compared to the standard diclofenac Na 87.17%, and in the tail immersion assay, the plant extract displayed a maximum average reaction time of 1.94 and 2.40 s at the doses of 250 and 500 mg/kg, respectively as compared to the control tramadol 2.84 s at 60 min. In an in vitro anti-inflammatory assay, the plant extract possessed an IC₅₀ of 95.51 μg/ml while diclofenac Na (standard drug) was found to be 69.50 μg/ml. Afterward, in vivo anti-inflammatory activity was observed in mice over a period, particularly after 3 h, the plant extract exerted maximum percent inflammation inhibitions of 36.36% and 45.45% at the doses of 250 and 500 mg/kg, respectively whereas ibuprofen the standard drug (100 mg/kg) exhibited 61.82%. The plant extract demonstrated antihyperglycemic activity, lowering blood sugar levels to 5.7 and 4.62 mM at doses of 250 and 500 mg/kg, respectively, as opposed to 8.58 mM in the control group. Meanwhile, the standard drug glibenclamide (5 mg/kg) dropped blood glucose levels to 2.38 mM in 60 min after glucose administration. Molecular docking (MD) and molecular dynamics simulation (MDS) studies support the stability of the protein complex responsible for exerting pharmacological activities.CONCLUSIONA. capitiformis extract exhibited strong medicinal values supporting its traditional uses.

140

News (Medical) associated with Ibuprofen

18 Nov 2024

·www.drugs.com

Certain Painkillers Can Raise Bleeding Risks for People on Blood Thinners

MONDAY, Nov. 18, 2024 -- People on blood thinners have a doubled risk of dangerous internal bleeding if they also take a non-steroidal anti-inflammatory drug (NSAID) like ibuprofen or naproxen, a new study warns. People typically are prescribed blood thinners to treat or prevent strokes , heart attacks, or blood clots in the legs or lungs, researchers said. NSAIDs also are known to thin the blood, and the new study shows that they can increase risk of uncontrolled bleeding in the gut, brain, lungs and bladder if taken alongside a blood thinner. “We found that for patients taking blood thinners for blood clots in the legs or lungs, using NSAIDs doubled the risk of bleeding compared with not using NSAIDs,” said researcher Soren Riis Peterson , a medical student with Aarhus University Hospital in Denmark. “The increased bleeding risk associated with NSAID use was not limited to the digestive tract but also seemed to affect other organ systems.” For the study, researchers analyzed data on nearly 52,000 Danish patients prescribed a blood thinner to treat a blood clot between 2012 and 2022. In Denmark, the NSAIDs diclofenac and naproxen can only be obtained through a prescription. This allowed researchers to track the health of patients who had been prescribed both a blood thinner and an NSAID. Overall, the risk of a bleed was two times higher when people took a blood thinner and an NSAID, compared to just taking a blood thinner, researchers found. The specific risk was four times higher for naproxen, three times higher for diclofenac and nearly twice as high for ibuprofen. Specific bleed risks included: Using NSAIDs with a blood thinner also tripled a person’s risk of anemia, researchers found. The pattern of risk remained similar across a wide variety of blood thinners, including rivaroxaban , apixaban , dabigatran , edoxaban and warfarin , results show. The new study was published Nov. 17 in the European Heart Journal . “For people taking blood thinners for blood clots in their legs or lungs, our research highlights the importance of being cautious when considering NSAIDs for pain or inflammation,” Petersen concluded in a journal news release. “We recommend that patients consult their doctor before taking NSAIDs along with a blood thinner.” In an accompanying editorial, Dr. Robert Storey , a professor of clinical cardiology with the University of Sheffield in the U.K., noted that NSAIDs are widely used, making up about 8% of prescriptions worldwide and often available over-the-counter. “It seems clear that avoiding NSAIDs in combination with [blood thinners] is the safest strategy to avoid excess bleeding risk,” Storey wrote. “However, if this is not possible, what mitigation can be put in place? NSAID prescription should obviously be at the lowest dose and for the shortest time possible, but choice of agent and route may also be important.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA

18 Nov 2024

·www.drugs.com

Bleeding Risk Increased With NSAID Use for VTE Patients Receiving Anticoagulants

MONDAY, Nov. 18, 2024 -- Patients with venous thromboembolism (VTE) initiating oral anticoagulants have an increased risk for bleeding when using nonsteroidal anti-inflammatory drugs (NSAIDs), according to a study published online Nov. 17 in the European Heart Journal . Søren Riis Petersen, from Aarhus University Hospital in Denmark, and colleagues conducted a nationwide cohort study of 51,794 VTE patients initiating oral anticoagulants between Jan. 1, 2012, and Dec. 31, 2022. Adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes were computed. The researchers found that the event rates for any bleeding per 100 person-years were 3.5 and 6.3 during periods without and with NSAID use, respectively (number needed to harm, 36 patients treated for one year). The adjusted hazard ratios for any bleeding associated with NSAID use versus nonuse were 2.09, 1.79, 3.30, and 4.10 overall, for ibuprofen, for diclofenac, and for naproxen, respectively. The adjusted hazard ratios associated with NSAID use versus nonuse were 2.24, 3.22, 1.36, 1.57, and 2.99 for gastrointestinal bleeding, intracranial bleeding, thoracic and respiratory tract bleeding, urinary tract bleeding, and anemia caused by bleeding, respectively. For anticoagulant and VTE subtypes, the results were consistent. "The common use of NSAIDs in patients with cardiovascular disease emphasizes the importance of being aware of the bleeding risks associated with their use," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA

06 Nov 2024

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year. "For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical step forward," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "These designations not only recognize the urgent need for effective treatments but also provide vital support to accelerate research and development. These important regulatory milestones represent hope for families and a pathway to bring transformative medicines to a vulnerable patient population more quickly and efficiently." The U.S. FDA grants Rare Pediatric Disease Designation to incentivize drug development for life-threatening diseases affecting less than 200,000 children in the U.S. As these diseases pose unique challenges to drug development, special focus is needed to provide therapeutic options to these children. Companies that receive approval for a drug or biologic with this designation may be eligible for a voucher which may be redeemed for priority review of a different product. Additionally, this voucher may be transferred or sold to another sponsor. Orphan Drug Designation is granted by the U.S. FDA to encourage development of new therapies for rare diseases or conditions affecting fewer than 200,000 people in the U.S. This designation offers sponsors multiple incentives, which include exemption from user fees, tax credits for qualified clinical trials and potential market exclusivity for seven years following approval of the product. About Duchenne Muscular Dystrophy DMD is a rare and fatal genetic disorder which affects about 1 in every 3,300 male births worldwide. Characterized by mutations in the gene responsible for producing dystrophin, DMD causes damage to the skeletal and cardiac muscle of DMD patients, with cardiomyopathy recognized as the primary cause of death. Ifetroban is being evaluated to treat the heart disease associated with DMD, which has received limited attention with current therapies. About Ifetroban Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell types including cardiomyocytes, platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity. In several preclinical models of muscular dystrophy, including limb-girdle and Duchenne, ifetroban prevented cardiac fibrosis and cardiac dysfunction and improved mortality. Cumberland previously announced the acquisition of the ifetroban program in collaboration with Vanderbilt University and Cumberland Emerging Technologies. Cumberland is also evaluating ifetroban for systemic sclerosis and pulmonary fibrosis. The ongoing FIGHTING FIBROSIS Trial is a multicenter, randomized placebo-controlled Phase II study in patients with idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease. IPF is marked by inflammation and fibrosis of the lungs, resulting in rapidly declining lung function and reduced survival within five years of diagnosis. The study is evaluating the safety and efficacy of once daily oral Ifetroban for 52 weeks. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The Company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) Injection, for the treatment of pain and fever; Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; and Sancuso® (granisetron) Transdermal delivery system, for the treatment of nausea and vomiting associated with chemotherapy. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website . About Cumberland Emerging Technologies Cumberland Emerging Technologies, Inc. () is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies. Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Orphan DrugAcquisitionClinical Result

100 Deals associated with Ibuprofen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00126	Ibuprofen	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	DB01050

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ductus Arteriosus, Patent	EU	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	LI	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	IS	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	NO	Recordati Rare Diseases, Inc.	28 Jul 2004
Chronic Pain	AU	Viatris Pty Ltd.	12 Nov 2001
Juvenile Idiopathic Arthritis	AU	Viatris Pty Ltd.	12 Nov 2001
Osteoarthritis	AU	Viatris Pty Ltd.	12 Nov 2001
Primary dysmenorrhea	AU	Viatris Pty Ltd.	12 Nov 2001
Acute upper respiratory infection	JP	Kaken Pharmaceutical Co., Ltd.	25 Jun 1971
Inflammation	JP	Kaken Pharmaceutical Co., Ltd.	25 Jun 1971
Rheumatoid Arthritis	GB	Johnson & Johnson	01 Jan 1969
Arthritis	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966
Fever	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966
Pain	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fever	Phase 3	TH	Cumberland Pharmaceuticals, Inc.	01 Jun 2002
Osteoarthritis	Phase 3	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Pain	Phase 3	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Pain	Phase 3	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Fever	Phase 2	TH	Cumberland Pharmaceuticals, Inc.	01 Jun 2002
Pain	Phase 2	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PRNewswire Manual	Not Applicable	Pain	-	Caldolor (ibuprofen) injection	ytjjcqzjdw(qemjynxnmk) = fagpwfggqb odajrsrcwz (zujpwokzdm ) View more	Positive	05 Nov 2024
				ketorolac	-
NCT04611529 (CTgov)	Phase 4	Acute low back pain	198	Topical diclofenac+Ibuprofen 400 mg (Oral Ibuprofen + Topical Diclofenac)	grhzcmxrfn(xfjaacegtn) = caytlqzvue kfxphnxzgd (iymaqtkgva, jmzuasnfek - igunprynar) View more	-	09 Oct 2024
				Ibuprofen 400 mg (Oral Ibuprofen + Topical Placebo)	grhzcmxrfn(xfjaacegtn) = infvwxdvbr kfxphnxzgd (iymaqtkgva, qicpfodbmy - ktppmdnhrq) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	dmixwfcdpf(nvbkqixsvf) = wegakwrhkq wwbcogimoo (zqhbfaeduc, zmzdfjszzp - yzgxcmwdnl) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	dmixwfcdpf(nvbkqixsvf) = szqxlrzqyw wwbcogimoo (zqhbfaeduc, vzqoaczqda - rpbgplyncp) View more
NCT05737069 (CTgov)	Phase 1	Pain	84	Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test))	mytalrurld(gsbuqacsyk) = bjxkcziaij khnyuvdzuz (vgsxzggnqu, gkcezzojas - ftlvbqitfk) View more	-	19 Sep 2024
				Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference))	mytalrurld(gsbuqacsyk) = bgaqzkmocd khnyuvdzuz (vgsxzggnqu, gryvfflpul - nxpvhijlng) View more
NCT04879823 (CTgov)	Phase 3	Analgesia	222	Acetaminophen+Ibuprofen+Dexamethasone (Dexamethasone)	yqhwncsexu(oawxcwrkvw) = lgwegfixed dgvwrbavnt (lfmtdkjwbl, wmzsfvfjqh - gewsnetkxw) View more	-	05 Sep 2024
				Placebo+Acetaminophen+Ibuprofen (Placebo)	yqhwncsexu(oawxcwrkvw) = tdkevoleew dgvwrbavnt (lfmtdkjwbl, fkxcxdpebm - qamoxcsxxa) View more
NCT03749616 (Adult NSAID, CTgov)	Phase 4	Pain \| Radius Fractures	32	Acetaminophen (Acetaminophen)	fcyudfrkvo(anvlpvpeav) = zxdwwqbhpy gncqwmagkq (vzwtnxgzja, xvcnngrvsa - pqlemygnvz) View more	-	05 Sep 2024
				Ibuprofen (NSAID)	fcyudfrkvo(anvlpvpeav) = bjwqstvpja gncqwmagkq (vzwtnxgzja, bgqghshelj - drtllztafz) View more
NCT03929640 (CTgov)	Phase 3	Pain, Postoperative	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	nymwyqytyt(pfnzeowiph) = kdhfpmdqsq lpmaqqtule (joiqkrpwdj, zikiadbnej - cehsrfayjd) View more	-	04 Sep 2024
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	nymwyqytyt(pfnzeowiph) = sblqtdaano lpmaqqtule (joiqkrpwdj, ncbqphvkbr - osyaauvbwm) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	wxkcykakwe(xccxwyzjyc) = xbvsjktxgt qwayfsdisa (hgcjuuvsdm, gyrtlnpoos - wexxwonkpi) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	wxkcykakwe(xccxwyzjyc) = pqlkszbvzk qwayfsdisa (hgcjuuvsdm, miogslumqj - bulbidehnb) View more
NCT03399318 (Pubmed)	Phase 3	Malaria	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	omawutiwks(inzvwpooyu) = vtquqlbgls mewnemhvtb (jleldbkpen, -0.62) View more	Positive	10 Jun 2024
				Usual care (acetaminophen alone)	omawutiwks(inzvwpooyu) = fhjqxyclmf mewnemhvtb (jleldbkpen, -0.82 to -0.42) View more
NCT03785756 (CTgov)	Phase 3	Pain	280	Placebo of IR tablet+Ibuprofen 300 mg Oral Tablet (Prolonged Release Group)	upwcvtppiz(czkctxmifi) = rhacaknuqy enoffgrmjd (qpcckwtwdj, exziocyhjd - gtygtlnvmj) View more	-	03 Jun 2024
				Placebo of IR tablet+Ibuprofen 200 mg Oral Tablet (Immediate Release Group)	upwcvtppiz(czkctxmifi) = bpacyfoavo enoffgrmjd (qpcckwtwdj, rfywclyclp - mywynnyqtq) View more